key: cord-1040583-uqdnkl0d
authors: Hirai, Daisuke; Yamashita, Daisuke; Seta, Koichi
title: Favipiravir for COVID-19 in a Patient on Hemodialysis
date: 2020-10-01
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2020.09.007
sha: 09dcf2e7ab11481f2b1e69bd5f38c8f935e6249f
doc_id: 1040583
cord_uid: uqdnkl0d

nan

Favipiravir (FPV) may be one effective option for treating SARS-CoV-2 (COVID-19)-infected ESRD patients. 1 There have been few reports of FPV administration in hemodialysis patients. We administered FPV to a hemodialysis patient with COVID-19 and found that blood concentrations of FPV were similar to those seen in patients not on dialysis.

A 72-year-old man presented with fever and cough at an outside hospital. Chest The course of the decline in FPV blood concentration we observed was similar to that reported in patients not on hemodialysis. 2, 3 This was unexpected, since the molecular weight of FPV is 157, the protein binding rate is 53%-54%, and the volume of distribution is about 20 liters, suggesting that dialysis would eliminate FPV.

The half-maximal effective concentration (EC50) against SARS-CoV-2 is 9.7 μg/mL, J o u r n a l P r e -p r o o f but the blood concentrations after day 9 were all below this level. 4 Previous reports also indicated that blood concentrations of FPV were lower than predicted and that therapeutic drug monitoring was may be necessary. 2

Items S1: Methods for administration of favipiravir and measurement of blood concentration.

Support: None. 

Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. CEN Case Rep

Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro